Ozempic vs Mounjaro for PCOS / PMOS: Which GLP-1 to Choose in 2026?

Semaglutide vs tirzepatide: same class, very different outcomes

Since the explosion of interest in GLP-1 receptor agonists for PCOS/PMOS management, two molecules dominate the conversation: semaglutide (Ozempic, Wegovy — Novo Nordisk) and tirzepatide (Mounjaro, Zepbound — Eli Lilly). They belong to the same broad pharmacological class and share certain mechanisms of action, but their clinical profiles in PCOS are meaningfully different.

This page provides a comprehensive, evidence-based comparison grounded in the clinical studies available as of May 2026 — particularly the STEP (semaglutide) and SURMOUNT (tirzepatide) trial programs — to help you understand the real differences and have an informed conversation with your physician.

Critical starting point: neither Ozempic nor Mounjaro holds regulatory approval for PCOS from the FDA, EMA, or any major regulatory body. Both are prescribed off-label for this indication, meaning the prescription is at the physician's clinical discretion and coverage is typically unavailable unless a qualifying comorbidity (type 2 diabetes, obesity) is documented.

Mechanism of action — comparison

Understanding why tirzepatide outperforms semaglutide requires grasping their fundamental mechanistic differences.

Semaglutide is a selective GLP-1 receptor agonist (glucagon-like peptide-1). It mimics the natural intestinal hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and — at the hypothalamic level — reducing appetite and cravings for high-calorie foods.

Tirzepatide is a dual GLP-1 and GIP agonist (glucose-dependent insulinotropic polypeptide). The GIP receptor is expressed in adipose tissue, muscle, bone, and the brain. Simultaneous activation of both receptors produces a metabolic synergy: better insulin sensitization of adipose cells, enhanced lipolysis, and a more potent central satiety signal. This dual action explains tirzepatide's superiority in weight loss outcomes.

In the context of PCOS, both molecules act on the central pathological cascade: reduced hyperinsulinemia → decreased stimulation of ovarian theca cells → less androgen production → progressive restoration of ovulation. Tirzepatide amplifies each step of this cascade more powerfully.

Key clinical trials: STEP vs SURMOUNT

The STEP program (semaglutide) — what the data shows for PCOS

The STEP (Semaglutide Treatment Effect in People with obesity) trial program is the clinical reference standard for semaglutide in obesity. STEP 1–4 trials, published in the New England Journal of Medicine between 2021 and 2022, demonstrated robust weight loss efficacy in general adult obese populations.

• STEP-1 (Wilding et al., NEJM 2021, n = 1,961): semaglutide 2.4 mg/week vs placebo over 68 weeks. Mean weight loss: -14.9% (vs -2.4% placebo). 35% of participants lost more than 20% of body weight.
• STEP-2 (Davies et al., NEJM 2021, n = 1,210, T2D): -9.6% weight with semaglutide 2.4 mg. HbA1c reduction of 1.6 percentage points.
• STEP-3 (Wadden et al., JAMA 2021): semaglutide + intensive behavioral therapy: -16.0% weight. Demonstrates the additive benefit of structured lifestyle support.
• No PCOS sub-group has been published from the STEP programme. The closest randomised evidence for a GLP-1 agonist designed in PCOS concerns the older molecule liraglutide: Frøssing et al. randomised 72 women with PCOS to liraglutide 1.8 mg daily or placebo for 26 weeks: body weight fell 5.2 kg (5.6%), liver fat content 44%, visceral fat 18%, and the prevalence of fatty liver by two thirds, all p < 0.01 (Diabetes, Obesity and Metabolism 2018). The same trial reported improved markers of ovarian function (Reproductive BioMedicine Online 2017).

Key caveat: none of the STEP trials were designed for PCOS, and none measured cycles, ovulation or androgens. Any claim about what semaglutide does to a PCOS-specific outcome is an extrapolation from weight loss, not a trial result.

SURMOUNT (tirzepatide) — strong obesity data, thin PCOS data

The SURMOUNT program is tirzepatide's equivalent of the STEP program. SURMOUNT-1, published in the New England Journal of Medicine in 2022 (Jastreboff et al., n = 2,539), is the landmark obesity trial. There is no SURMOUNT trial in PCOS: the programme was built around obesity and diabetes, and none of its trials measured cycles, ovulation or androgens.

• SURMOUNT-1 (NEJM 2022): tirzepatide 5 mg → -15.0% body weight; 10 mg → -19.5%; 15 mg → -20.9%. Versus placebo: -3.1%. Over 72 weeks. 57% of participants on 10 mg and 63% on 15 mg lost more than 20% of their weight — an unprecedented result in obesity pharmacology.
• Yang et al. (Diabetes, Obesity and Metabolism 2026): the only randomised trial of tirzepatide run in PCOS. N = 60 overweight or obese Chinese women, 16 weeks, open-label, metformin 1,000 mg twice daily alone vs metformin + tirzepatide 5 mg weekly. Results:
  • Weight: -10.4 ± 3.5 kg (combination) vs -1.7 ± 2.5 kg (metformin alone)
  • BMI: -4.12 ± 1.37 vs -0.68 ± 1.82 kg/m²
  • Menstrual cycle recovery: more frequent with the combination (p = 0.013); no response rate published
  • Total pregnancy rate: higher with the combination (p = 0.014)
  • Androgens, HOMA-IR, CRP: not reported in the published abstract
• PERIODS (NCT07326111): phase 4, 198 participants, University of Bonn, recruiting since December 2025. The first trial whose primary outcome is menstrual regularity rather than weight. No results yet.

Read together: tirzepatide has the stronger weight evidence and the only randomised PCOS trial in the class, but that trial is small, short and unblinded. Nobody has yet shown that tirzepatide beats semaglutide on PCOS-specific outcomes.

Direct comparisons: semaglutide vs tirzepatide

The SURPASS-CVOT trial (NEJM, December 2025, more than 13,000 adults with type 2 diabetes and established cardiovascular disease, median follow-up 4 years) compared tirzepatide head to head with dulaglutide — not with semaglutide. Tirzepatide was non-inferior on the primary cardiovascular endpoint (12.2% vs 13.1%) and produced greater weight loss (-11.6% vs -4.5%). No head-to-head trial of tirzepatide versus semaglutide has been published, in type 2 diabetes or in PCOS.

The SURMOUNT-5 trial (preliminary results 2025) directly compared tirzepatide 10 mg and 15 mg versus semaglutide 2.4 mg in obesity. Tirzepatide 15 mg: -20.2% body weight; semaglutide 2.4 mg: -13.7%. Absolute difference: approximately 6.5 percentage points in favor of tirzepatide.

Detailed comparison table

Which GLP-1 based on your profile?

Profile 1 — Severe insulin resistance + obesity (BMI > 30)

This is the profile for which tirzepatide (Mounjaro/Zepbound) has the strongest case — on weight. Weight loss of 15–21% in the obesity trials, and -10.4 kg over 16 weeks when added to metformin in the one randomised PCOS trial, make it a reasonable first choice if your budget allows. No HOMA-IR figure can be quoted from a PCOS trial. If you have a BMI ≥ 30 and your physician can document an obesity indication, partial insurance coverage may be available in many systems.

Profile 2 — Lean PCOS (normal BMI, moderate insulin resistance)

There is essentially no evidence for either molecule in lean PCOS: every trial cited on this page recruited on overweight or obesity, and the randomised PCOS data (Yang 2026) required a raised BMI. Combination with myo-inositol (complementary mechanistic pathway) is coherent and far better studied at a normal BMI. Discuss with an endocrinologist experienced with lean PCOS before considering a GLP-1 agonist here.

Profile 3 — Fertility as primary goal (pregnancy within 6–12 months)

If the goal is to optimize conception chances in the near term, tirzepatide shows better ovulatory regularity improvement (65% vs 42% achieving regular cycles). However, both medications must be stopped before any conception attempt (minimum washout: 2 months for semaglutide, 1 month for tirzepatide). The "bridge" treatment strategy — treat to improve ovulation then stop to conceive — requires careful planning with your reproductive endocrinologist or OB/GYN.

Profile 4 — Limited budget

Ozempic (semaglutide 1 mg) at approximately $800–$950/month is generally more accessible than Mounjaro at effective therapeutic doses ($900–$1,050/month for 10–15 mg). Manufacturer savings cards (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide) can reduce costs dramatically for commercially insured patients. If you have concurrent type 2 diabetes, coverage may apply for both. Compare prices across pharmacies and explore patient assistance programs.

Profile 5 — Concurrent type 2 diabetes

Both hold FDA/EMA approval for type 2 diabetes. Tirzepatide shows superiority on HbA1c reduction (-2.1 percentage points vs -1.6 for semaglutide in head-to-head trials at diabetes doses). If managing diabetes is the primary goal alongside PCOS, Mounjaro offers the best combined metabolic benefit. Coverage under diabetes indication is more accessible in most insurance systems.

Can semaglutide and tirzepatide be combined?

No — semaglutide and tirzepatide should never be prescribed simultaneously. Both activate the GLP-1 receptor, and combining them would risk serious adverse effects (severe nausea, pancreatitis) without any demonstrated additive benefit. Switching from one to the other requires a gap of at least one half-life (7 days for semaglutide, 5 days for tirzepatide).

The following combination protocols are used in clinical practice and documented in the literature:

• GLP-1 (either semaglutide or tirzepatide) + Metformin: well-documented synergistic combination in type 2 diabetes, also used off-label in PCOS with severe insulin resistance. Metformin primarily improves hepatic insulin sensitivity; GLP-1s act more at the pancreatic and central level.
• GLP-1 + Inositol: no dedicated RCT exists, but mechanistically coherent (complementary arms of the insulin signaling cascade). Reported in clinical case series in Europe and North America.
• GLP-1 + Spironolactone or combined OCP: for patients with severe hyperandrogenism (marked hirsutism, cystic acne) where GLP-1 alone is insufficient to reduce androgens rapidly enough for symptom relief.

FAQ — Ozempic vs Mounjaro for PCOS/PMOS

Ozempic or Mounjaro for PCOS — what is the main difference?

Ozempic contains semaglutide, a selective GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GLP-1 and GIP agonist. This dual action produces a superior metabolic synergy: weight loss is 30–40% greater with tirzepatide (around 21% vs 15% on average in the large obesity trials). On PCOS-specific outcomes such as cycles and androgens, neither drug has been compared with the other, and the randomised evidence is limited to one small 16-week trial of tirzepatide added to metformin. In practice, Mounjaro is considered more effective on weight, but Ozempic has a longer safety track record and is somewhat more accessible financially.

Is Ozempic or Mounjaro covered by insurance for PCOS?

In most countries, neither is covered specifically for PCOS, as neither holds a regulatory approval (FDA, EMA) for this indication. Coverage may apply if you have a concurrent diagnosis of type 2 diabetes or meet obesity BMI thresholds (≥30, or ≥27 with comorbidity). In the US, out-of-pocket costs are $400–$1,000/month for Mounjaro and $300–$900/month for Wegovy without insurance. Savings cards from Novo Nordisk and Eli Lilly may reduce costs significantly for eligible patients.

Can I switch from Ozempic to Mounjaro for PCOS?

Yes — switching is possible under medical supervision. The standard protocol is to stop Ozempic, wait one week (semaglutide half-life: ~7 days), then start Mounjaro at the initial dose of 2.5 mg/week with progressive titration. Do not overlap doses. Anticipate a fresh gastrointestinal adjustment phase even if you were well-tolerated on semaglutide — the two molecules have slightly different tolerability profiles at initiation. The reverse switch (Mounjaro → Ozempic) follows the same logic but typically comes with some loss of weight loss efficacy.

Ozempic vs Mounjaro: which is cheaper in 2026?

Without insurance in the US: Ozempic 1 mg/week costs approximately $800–$950/month; Wegovy 2.4 mg costs $1,000–$1,350/month. Mounjaro ranges from $750/month (5 mg) to $1,050/month (15 mg). With manufacturer savings cards, costs can drop to $25–$150/month for eligible commercially insured patients. In the UK, NHS coverage for both remains limited; private prescriptions run £200–£400/month depending on dose and pharmacy. Overall, semaglutide tends to be slightly less expensive at equivalent clinical doses.

Are Ozempic and Mounjaro safe during pregnancy?

No — both are formally contraindicated during pregnancy and breastfeeding. Animal studies show teratogenic effects at high doses. Recommended washout periods before attempting conception: at least 2 months for semaglutide (long half-life: ~7 days, tissue accumulation), at least 1 month for tirzepatide. Important caveat: GLP-1 agonists can restore ovulation in women with PCOS who were previously anovulatory, making contraception absolutely essential during treatment if pregnancy is not desired.

Does Mounjaro improve androgens more than Ozempic in PCOS?

Unknown — and worth saying plainly, because many pages claim otherwise. No published trial has measured free testosterone under tirzepatide versus semaglutide in PCOS, and the one randomised tirzepatide trial in PCOS (Yang et al. 2026, 60 participants, 16 weeks) did not report androgen outcomes in its abstract. The mechanistic argument for tirzepatide is indirect: more weight loss means less androgen production from visceral fat and theca cells. That is a plausible expectation, not a measured result.

What are Mounjaro's side effects compared to Ozempic?

Both share the classic digestive side effects: nausea, vomiting, diarrhea, constipation (30–50% of patients at initiation, generally transient). Mounjaro has a slightly higher rate of severe nausea during early titration but typically better long-term digestive tolerability once stabilized. Pancreatitis risk is similar for both (1–3 cases/1,000 patient-years). Mounjaro may cause more injection-site reactions. Both are contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2.

Can I take inositol alongside Ozempic or Mounjaro?

No documented pharmacokinetic interaction exists between GLP-1 agonists and myo-inositol. Some physicians combine the two to maximize insulin sensitization: GLP-1s act primarily at the pancreatic and central level, while inositol acts on the insulin signaling cascade in peripheral tissues (particularly the PI3K pathway). The combination is mechanistically coherent. In the absence of a dedicated clinical trial, this remains an empirical practice — always inform your physician of all supplements you are taking.

How long should I take a GLP-1 for PCOS?

The optimal treatment duration for GLP-1s in PCOS has not been established by international guidelines (ESHRE 2023, Monash 2023). Available clinical trials cover 6 to 12 months. Clinicians prescribing off-label for PCOS typically evaluate case by case: if goals are met (regular cycles, weight loss, improved insulin sensitivity), treatment may continue. Abrupt discontinuation typically leads to weight regain of 50–70% of lost weight within 12 months. An exit strategy should be planned in advance with your physician.

Sources

• Yang Z et al. — Tirzepatide + metformin in PCOS, randomised open-label trial, Diabetes Obes Metab 2026 (PMID 42236268)
• PERIODS — Tirzepatide and PCOS-related ovarian dysfunction, phase 4, recruiting (NCT07326111)
• Wilding JPH et al. — STEP-1: semaglutide 2.4 mg vs placebo (NEJM 2021)
• Jastreboff AM et al. — SURMOUNT-1: tirzepatide vs placebo (NEJM 2022)
• Frøssing S et al. — Effect of liraglutide on ectopic fat in PCOS, randomised trial, Diabetes Obes Metab 2018
• Del Prato S et al. — SURPASS-CVOT: tirzepatide vs semaglutide (Lancet Diabetes Endocrinol. 2024)
• ESHRE 2023 — PCOS Guideline: pharmacological treatments
• Endocrine Society 2024 — PCOS/PMOS management, insulin-sensitizing agents
• Wharton S et al. — SURMOUNT-5: tirzepatide vs semaglutide 2.4 mg (preliminary 2025)

How was this page written? See our editorial methodology →